KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to $4.3 million.

  • AbCellera Biologics' Depreciation & Amortization (CF) rose 13.16% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 7.06%. This contributed to the annual value of $12.5 million for FY2024, which is 2.05% down from last year.
  • Latest data reveals that AbCellera Biologics reported Depreciation & Amortization (CF) of $4.3 million as of Q3 2025, which was down 4.44% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Depreciation & Amortization (CF) registered a high of $4.5 million during Q2 2025, and its lowest value of $840,000 during Q1 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $3.4 million (2024), whereas its average is $3.5 million.
  • As far as peak fluctuations go, AbCellera Biologics' Depreciation & Amortization (CF) skyrocketed by 113.97% in 2022, and later slumped by 46.15% in 2024.
  • Quarterly analysis of 5 years shows AbCellera Biologics' Depreciation & Amortization (CF) stood at $1.3 million in 2021, then surged by 113.97% to $2.8 million in 2022, then skyrocketed by 39.89% to $3.9 million in 2023, then crashed by 46.15% to $2.1 million in 2024, then climbed by 13.16% to $4.3 million in 2025.
  • Its Depreciation & Amortization (CF) was $4.3 million in Q3 2025, compared to $4.5 million in Q2 2025 and $4.4 million in Q1 2025.